Alpelisib in Intractable Non-Islet-Cell Tumor Hypoglycemia.

Avivit Cahn; Hagit Shoyhet-Smoilovsky; Matan Fischer; Aviad Zick; Yael Riahi; Shulamit Levenberg; Gil Leibowitz

doi:10.1056/NEJMc2302935

Alpelisib in Intractable Non-Islet-Cell Tumor Hypoglycemia.

Avivit Cahn, Hagit Shoyhet-Smoilovsky, Matan Fischer, Aviad Zick, Yael Riahi, Shulamit Levenberg, Gil Leibowitz

Technion - Israel Institute of Technology, The Hebrew University of Jerusalem

Research output: Contribution to journal › Review article › peer-review

Abstract

Alpelisib in Intractable Non-Islet-Cell Tumor Hypoglycemia This letter describes the use of alpelisib, a PI3 kinase inhibitor, to successfully treat severe hypoglycemia in a patient with intractable non-islet-cell tumor hypoglycemia.

Original language	English
Pages (from-to)	1911-1913
Number of pages	3
Journal	New England Journal of Medicine
Volume	388
Issue number	20
DOIs	https://doi.org/10.1056/NEJMc2302935
State	Published - 18 May 2023

Keywords

Clinical Medicine
Clinical Medicine General
Endocrinology
Endocrinology General
Hematology/Oncology
Treatments in Oncology

All Science Journal Classification (ASJC) codes

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJMc2302935

Cite this

@article{a86e9138b7fa487a95c2aa352a5b237c,

title = "Alpelisib in Intractable Non-Islet-Cell Tumor Hypoglycemia.",

abstract = "Alpelisib in Intractable Non-Islet-Cell Tumor Hypoglycemia This letter describes the use of alpelisib, a PI3 kinase inhibitor, to successfully treat severe hypoglycemia in a patient with intractable non-islet-cell tumor hypoglycemia.",

keywords = "Clinical Medicine, Clinical Medicine General, Endocrinology, Endocrinology General, Hematology/Oncology, Treatments in Oncology",

author = "Avivit Cahn and Hagit Shoyhet-Smoilovsky and Matan Fischer and Aviad Zick and Yael Riahi and Shulamit Levenberg and Gil Leibowitz",

note = "Publisher Copyright: {\textcopyright} 2023 Massachusetts Medical Society.",

year = "2023",

month = may,

day = "18",

doi = "10.1056/NEJMc2302935",

language = "الإنجليزيّة",

volume = "388",

pages = "1911--1913",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "20",

}

TY - JOUR

T1 - Alpelisib in Intractable Non-Islet-Cell Tumor Hypoglycemia.

AU - Cahn, Avivit

AU - Shoyhet-Smoilovsky, Hagit

AU - Fischer, Matan

AU - Zick, Aviad

AU - Riahi, Yael

AU - Levenberg, Shulamit

AU - Leibowitz, Gil

PY - 2023/5/18

Y1 - 2023/5/18

N2 - Alpelisib in Intractable Non-Islet-Cell Tumor Hypoglycemia This letter describes the use of alpelisib, a PI3 kinase inhibitor, to successfully treat severe hypoglycemia in a patient with intractable non-islet-cell tumor hypoglycemia.

AB - Alpelisib in Intractable Non-Islet-Cell Tumor Hypoglycemia This letter describes the use of alpelisib, a PI3 kinase inhibitor, to successfully treat severe hypoglycemia in a patient with intractable non-islet-cell tumor hypoglycemia.

KW - Clinical Medicine

KW - Clinical Medicine General

KW - Endocrinology

KW - Endocrinology General

KW - Hematology/Oncology

KW - Treatments in Oncology

UR - http://www.scopus.com/inward/record.url?scp=85159756895&partnerID=8YFLogxK

U2 - 10.1056/NEJMc2302935

DO - 10.1056/NEJMc2302935

M3 - مقالة مرجعية

C2 - 37195951

SN - 0028-4793

VL - 388

SP - 1911

EP - 1913

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 20

ER -

Alpelisib in Intractable Non-Islet-Cell Tumor Hypoglycemia.

Abstract

Keywords

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this